PHOTONIS GROUP a global leader of highly differentiated technology for detection, imaging and light, held by Groupe HLD since 2021 is deeply transforming by developing adjacent technologies, expanding to particles detection markets.
Following that strategy, the group has acquired four companies (Xenics, Proxivision, Telops and Elmul) since December 2022. Worldwide leader for image intensifier tubes, the company has diversified its technologies and products portfolios with the ambition to become the worldwide leader in detection and imaging technologies. To illustrate that strategy, PHOTONIS GROUP becomes EXOSENS.
Proposing electro-optic devices covering the full optical spectrum from UV to LWIR in addition to electron, ion, neutron and gamma detectors, EXOSENS addresses four markets which are lifescience, industrial control, nuclear energy and defense. The company takes benefits of positive dynamics in each of these four verticals, such as enhanced diagnosis demand, factory automation, small modular reactors deployment and defense budget increase.
It’s an important step for Photonis Group. By becoming EXOSENS, the company clearly anchors its position as high-end technology provider to serve high growing commercial and defense markets for more sustainability and safety.
Jean-Hubert Vial, partner at Groupe HLD
EXOSENS means “to detect, to see and to give meaning to what is beyond”. It perfectly reflects what we are doing, we reveal the invisible, we sense the world to make it safer. With EXOSENS, we aim to share our common values throughout the whole organization, to integrate new companies and colleagues and to always offer high performances products to meet customers satisfaction.
Jérôme Cerisier, CEO of the EXOSENS
Operationally, legal entities will keep their existing names. The four product brands Photonis (for intensified products, nuclear and mass spectrometry detectors), Xenics (for infrared sensors and cameras), Elmul (for electron detectors) and Telops (for hyperspectral and cooled infrared camera) will continue to be deployed and promoted in their markets.
Souce: EXOSENS news release
